Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Tumorigenicity studies for human pluripotent stem cell-derived products.

Kuroda T, Yasuda S, Sato Y.

Biol Pharm Bull. 2013;36(2):189-92. Review.

2.

The safety of human pluripotent stem cells in clinical treatment.

Simonson OE, Domogatskaya A, Volchkov P, Rodin S.

Ann Med. 2015;47(5):370-80. doi: 10.3109/07853890.2015.1051579. Epub 2015 Jul 6. Review.

PMID:
26140342
3.

Tumorigenicity assessment of human cell-processed therapeutic products.

Yasuda S, Sato Y.

Biologicals. 2015 Sep;43(5):416-21. doi: 10.1016/j.biologicals.2015.05.008. Epub 2015 Jun 9.

PMID:
26071041
5.

Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine.

Knoepfler PS.

Stem Cells. 2009 May;27(5):1050-6. doi: 10.1002/stem.37. Review.

6.

Effects of histocompatibility and host immune responses on the tumorigenicity of pluripotent stem cells.

Dressel R.

Semin Immunopathol. 2011 Nov;33(6):573-91. doi: 10.1007/s00281-011-0266-8. Epub 2011 Apr 4. Review.

7.

Genetic and epigenetic instability in human pluripotent stem cells.

Nguyen HT, Geens M, Spits C.

Hum Reprod Update. 2013 Mar-Apr;19(2):187-205. doi: 10.1093/humupd/dms048. Epub 2012 Dec 7. Review.

PMID:
23223511
8.

[Regulatory science research to facilitate the development of cell/tissue-processed products].

Sato Y, Tsutsumi H, Sawada R, Suzuki T, Yasuda S.

Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku. 2013;(131):16-9. Review. Japanese.

PMID:
24340665
9.

Viral Vector-Based Innovative Approaches to Directly Abolishing Tumorigenic Pluripotent Stem Cells for Safer Regenerative Medicine.

Mitsui K, Ide K, Takahashi T, Kosai KI.

Mol Ther Methods Clin Dev. 2017 Mar 18;5:51-58. doi: 10.1016/j.omtm.2017.03.002. eCollection 2017 Jun 16. Review.

10.

Stable propagation of human embryonic and induced pluripotent stem cells on decellularized human substrates.

Abraham S, Sheridan SD, Miller B, Rao RR.

Biotechnol Prog. 2010 Jul-Aug;26(4):1126-34. doi: 10.1002/btpr.412.

PMID:
20730767
11.

Defining the nature of human pluripotent stem cell progeny.

Patterson M, Chan DN, Ha I, Case D, Cui Y, Van Handel B, Mikkola HK, Lowry WE.

Cell Res. 2012 Jan;22(1):178-93. doi: 10.1038/cr.2011.133. Epub 2011 Aug 16.

12.

Clinical-scale purification of pluripotent stem cell derivatives for cell-based therapies.

Rodrigues GM, Rodrigues CA, Fernandes TG, Diogo MM, Cabral JM.

Biotechnol J. 2015 Aug;10(8):1103-14. doi: 10.1002/biot.201400535. Epub 2015 Apr 8. Review.

PMID:
25851544
13.

Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies.

Abbasalizadeh S, Baharvand H.

Biotechnol Adv. 2013 Dec;31(8):1600-23. doi: 10.1016/j.biotechadv.2013.08.009. Epub 2013 Aug 17. Review.

PMID:
23962714
14.

Multipotent vasculogenic pericytes from human pluripotent stem cells promote recovery of murine ischemic limb.

Dar A, Domev H, Ben-Yosef O, Tzukerman M, Zeevi-Levin N, Novak A, Germanguz I, Amit M, Itskovitz-Eldor J.

Circulation. 2012 Jan 3;125(1):87-99. doi: 10.1161/CIRCULATIONAHA.111.048264. Epub 2011 Nov 17.

15.

Immunocytochemical analysis of human pluripotent stem cells using a self-made cytospin apparatus.

Pascual EY, Riggs MJ, Rao RR.

J Vis Exp. 2010 Apr 9;(38). pii: 1944. doi: 10.3791/1944.

16.

The tumorigenic potential of pluripotent stem cells: What can we do to minimize it?

Peterson SE, Garitaonandia I, Loring JF.

Bioessays. 2016 Jul;38 Suppl 1:S86-95. doi: 10.1002/bies.201670915. Review.

PMID:
27417126
17.

In vivo evaluation of putative hematopoietic stem cells derived from human pluripotent stem cells.

Hexum MK, Tian X, Kaufman DS.

Methods Mol Biol. 2011;767:433-47. doi: 10.1007/978-1-61779-201-4_32.

PMID:
21822894
18.

Design of a Tumorigenicity Test for Induced Pluripotent Stem Cell (iPSC)-Derived Cell Products.

Kawamata S, Kanemura H, Sakai N, Takahashi M, Go MJ.

J Clin Med. 2015 Jan 14;4(1):159-71. doi: 10.3390/jcm4010159. Review.

19.

Teratoma generation in the testis capsule.

Peterson SE, Tran HT, Garitaonandia I, Han S, Nickey KS, Leonardo T, Laurent LC, Loring JF.

J Vis Exp. 2011 Nov 7;(57):e3177. doi: 10.3791/3177.

20.

Modulating Glypican4 suppresses tumorigenicity of embryonic stem cells while preserving self-renewal and pluripotency.

Fico A, De Chevigny A, Egea J, Bösl MR, Cremer H, Maina F, Dono R.

Stem Cells. 2012 Sep;30(9):1863-74. doi: 10.1002/stem.1165.

Supplemental Content

Support Center